EMA Refused: Fanaptum (iloperidone) — Vanda Pharmaceuticals Ltd

View source ↗

Summary

The EMA refused the marketing authorization for Fanaptum (iloperidone) from Vanda Pharmaceuticals Ltd for schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Fanaptum (iloperidone)

Snippet

Status: Refused. Therapeutic area: Schizophrenia. MAH: Vanda Pharmaceuticals Ltd. Decision date: 15/01/2018